Vepdegestrant is being developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+/HER2- metastatic breast cancer. In July 2021, Arvinas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback